Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
Article
[키워드] adaptive
Administered
antibody
Asymptomatic
BNT162b2
Breakthrough infection
breakthrough infections
cellular
Cohort
COVID-19
COVID-19 pandemic
declined
determine
dose
effective
Follow-up
healthcare
humoral
humoral immune response
Hybrid immunity
IgG
immune
immune response
Immunity
Inclusion
increase in
individual
knowledge
Longitudinal assessment
Mild
mRNA vaccine
mRNA-1273
naïve
naïve individual
naïve individuals
neutralization
neutralizing antibody
peak level
Prevent
reached
reported
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 vaccination
SARS-CoV-2-specific T cells
second dose
T cell
T cells
third dose
triggered
vaccination
Vaccine
Viral antigen
[DOI] 10.3389/fimmu.2022.981350 PMC 바로가기
[DOI] 10.3389/fimmu.2022.981350 PMC 바로가기